Patents by Inventor Gillian M. Beattie

Gillian M. Beattie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030228287
    Abstract: The present invention provides a method of culturing cells on a matrix. The present invention includes islet cells cultured in a 3-D configuration in the presence of a fibrin matrix support. Induction of &bgr;-cell proliferation with HGF/SF is also provided.
    Type: Application
    Filed: October 18, 2002
    Publication date: December 11, 2003
    Applicant: Regents of the University of California
    Inventors: Gillian M. Beattie, Alberto Hayek, Anthony Montgomery
  • Publication number: 20030202967
    Abstract: This invention relates to cell lines, particularly mammalian cell lines, established by transforming the cells with vectors, preferably retroviral vectors, containing two or more oncogenes under the control of one or more inducible promoters and/or genetic elements. Also within the scope of the invention are human cell lines with extended in vitro lifespan, transformed by vectors containing one or more oncogenes under the control of one or more, preferably exogenous, inducible promoters and/or genetic elements. The vectors may additionally contain gene(s) encoding for desired gene product(s). Also disclosed are insulin producing human pancreatic cell lines useful for transplantation into human diabetic patients.
    Type: Application
    Filed: March 27, 2003
    Publication date: October 30, 2003
    Applicants: The Regents of the University of California, Whittier Institute for Diabetes and Endocrinology
    Inventors: Fred Levine, Sijian Wang, Gillian M. Beattie, Alberto Hayek
  • Patent number: 6413773
    Abstract: This invention pertains to the discovery that inhibition of phosphatidylinositol 3-kinase (PI3K) in human fetal undifferentiated cells induces morphological and functional endocrine differentiation. This is associated with an increase in mRNA levels of insulin, glucagon, and somatostatin, as well as an increase in the insulin protein content and secretion response to secretagogues. Blockade of PI3K also increases the proportion of pluripotent precursor cells coexpressing multiple hormones and the total number of terminally differentiated cells originating from these precursor cells.
    Type: Grant
    Filed: May 26, 1999
    Date of Patent: July 2, 2002
    Assignee: The Regents of the University of California
    Inventors: Andrezej Ptasznik, Alberti Hayek, Gillian M. Beattie
  • Publication number: 20020037276
    Abstract: This invention pertains to the discovery that inhibition of phosphatidylinositol 3-kinase (PI3K) in human fetal undifferentiated cells induces morphological and functional endocrine differentiation. This is associated with an increase in MRNA levels of insulin, glucagon, and somatostatin, as well as an increase in the insulin protein content and secretion response to secretagogues. Blockade of PI3K also increases the proportion of pluripotent precursor cells coexpressing multiple hormones and the total number of terminally differentiated cells originating from these precursor cells. In one embodiment, this invention thus rpov9des methods for endocrine differentiation in cultured cells.
    Type: Application
    Filed: May 26, 1999
    Publication date: March 28, 2002
    Inventors: ANDRZEJ PTASZNIK, ALBERTO HAYEK, GILLIAN M. BEATTIE
  • Patent number: 6110743
    Abstract: This invention relates to cell lines, particularly mammalian cell lines, established by transforming the cells with vectors, preferably retroviral vectors, containing two or more oncogenes under the control of one or more inducible promoters and/or genetic elements. Also within the scope of the invention are human cell lines with extended in vitro lifespan, transformed by vectors containing one or more oncogenes under the control of one or more, preferably exogenous, inducible promoters and/or genetic elements. The vectors may additionally contain gene(s) encoding for desired gene product(s). Also disclosed are insulin producing human pancreatic cell lines useful for transplantation into human diabetic patients.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: August 29, 2000
    Assignees: The Regents of the University of California, Whittier Institute for Diabetes and Endocrinology
    Inventors: Fred Levine, Sijian Wang, Gillian M. Beattie, Alberto Hayek
  • Patent number: 5874306
    Abstract: Human pancreatic endocrine cells are proliferated without loss of hormone function in a culture medium containing extracellular matrix from bladder carcinoma cell lines in the substantial absence of hepatocyte growth factor/scatter factor. Proliferation is preferably carried out in the substantial absence of any peptide growth factors and nicotinamide. The cells may be proliferated in a monolayer on a solid substrate. Islets and islet-like cell clusters are proliferated without loss of insulin-secreting function by incubation in a medium containing extracellular matrix from a human bladder carcinoma cell line, preferably cell line ATCC HTB-9.
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: February 23, 1999
    Assignee: The Regents of the University of California
    Inventors: Gillian M. Beattie, Alberto Hayek
  • Patent number: 5827741
    Abstract: The combination of trehalose and dimethyl sulfoxide is an unusually effective cryoprotectant for islets and islet-like cell clusters, as well as platelets. Islets and ICCs, when cooled through the thermotropic phase transition in the presence of this combination of treatment agents and then returned to physiologic temperature, retain their functionality. Likewise, platelets can be similarly cooled and warmed without undergoing premature activation. In general, trehalose can be incorporated into eukaryotic cells in general by suspending the cells in a trehalose solution and either cooling or warming the solution through the thermotropic transition of the cells.
    Type: Grant
    Filed: November 19, 1996
    Date of Patent: October 27, 1998
    Assignee: The Regents of the University of California
    Inventors: Gillian M. Beattie, John H. Crowe, Fern Tablin, Alberto Hayek
  • Patent number: 5723333
    Abstract: This invention relates to cell lines, particularly mammalian cell lines, established by transforming the cells with vectors, preferably retroviral vectors, containing two or more oncogenes under the control of one or more inducible promoters and/or genetic elements. Also within the scope of the invention are human cell lines with extended in vitro lifespan, transformed by vectors containing one or more oncogenes under the control of one or more, preferably exogenous, inducible promoters and/or genetic elements. The vectors may additionally contain gene(s) encoding for desired gene product(s). Also disclosed are insulin producing human pancreatic cell lines useful for transplantation into human diabetic patients.
    Type: Grant
    Filed: July 31, 1995
    Date of Patent: March 3, 1998
    Assignee: Regents of The University of California
    Inventors: Fred Levine, Sijian Wang, Gillian M. Beattie, Alberto Hayek
  • Patent number: 5587309
    Abstract: A method of inducing the proliferation and/or differentiation of human fetal pancreatic cells entails contacting such cells in primary culture with Hepatocyte Growth Factor/Scatter Factor, thereby inducing a proliferation of .beta.-epithelial cells, an increase in the number of .beta.-epithelial cells which form islet-like cell clusters, and an increase in insulin production per cell. The method provides increased numbers of functional islet-like cell clusters for transplantation, for example, into Type 1 diabetic patients. The method can be scaled up so as to provide clinically useful numbers of cells for transplantation.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: December 24, 1996
    Assignees: The United States of America as represented by the Department of Health and Human Services, Whittler Institute for Diabetes and Endocrinology
    Inventors: Jeffrey Rubin, Alberto Hayek, Gillian M. Beattie, Timo P. J. Otonkoski
  • Patent number: 5116753
    Abstract: The addition of basic FGF-saporin mitotoxins selectively elminates fibroblastoids from human islets in culture and increases the ability of such islets to release insulin under basal and stimulated conditions. When such islets are attached to an extracellular matrix, in particular BCEM, the proliferation of islet cells is favored, and the ability of islets cultured in such manner to release insulin is further increased. Moreover, supplementation of the culture media with high glucose or insulin further improves the functioning of the human islets, resulting in augmented insulin release. Combinations of such procedures offer a novel approach towards the establishment of viable human islet cell monolayers for clinical and laboratory research.
    Type: Grant
    Filed: July 30, 1991
    Date of Patent: May 26, 1992
    Assignees: The Salk Institute for Biological Studies, The Whittier Institute for Diabetes & Endocrinology
    Inventors: Gillian M. Beattie, Douglas A. Lappi, J. Andrew Baird, Alberto Hayek